Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
RTI Surgical Gains From HealthPartners' Nod for SI Surgery
by Zacks Equity Research
RTI Surgical's (RTIX) minimally invasive SImmetry System sees lucrative market prospects for the stock's growth.
Medtronic's Deal With Nutrino Health to Boost Diabetes Arm
by Zacks Equity Research
Bringing Nutrino under Medtronic's (MDT) Diabetes Group will help the acquirer speed up its growth in the same business.
Medtronic Gets Health Canada License for Visualase System
by Zacks Equity Research
Medtronic (MDT) adopts initiatives to boost top-line contributions from the Brain Therapies arm.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Strength in the surgical platform and an upbeat view for 2018 make Intuitive Surgical (ISRG) a promising pick.
Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified
by Zacks Equity Research
Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.
Intuitive Surgical (ISRG) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $485.24 in the latest trading session, marking a +0.53% move from the prior day.
Intuitive Surgical (ISRG) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
Intuitive Surgical (ISRG) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $498.64 in the latest trading session, marking a -0.95% move from the prior day.
GNC Holdings (GNC) Q3 Earnings Miss on Soft U.S. Retail
by Zacks Equity Research
GNC Holdings (GNC) discourages with sluggish domestic retail comps. However, it delivers a strong performance in e-commerce business as well as at International segment.
Looking for a Growth Stock? Why It is Time to Focus on Intuitive Surgical (ISRG)
by Zacks Equity Research
Intuitive Surgical (ISRG) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Phibro Animal (PAHC) Q1 Earnings Lag Estimates, Sales Up Y/Y
by Zacks Equity Research
Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.
OPKO Health (OPK) Incurs Loss in Q3, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE in Q3; adjusted gross margin remains pressed.
Haemonetics (HAE) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
athenahealth (ATHN) Q3 Earnings Beat, Bookings Down Y/Y
by Zacks Equity Research
athenahealth's (ATHN) Business and Services unit sees a strong Q3; 2018 guidance maintained.
DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.
Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) sees solid segmental performance in fiscal Q4; gains from alliance with Abbott.
Can Canadian Market Drive Canopy Growth (CGC) Q2 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses dismal segmental performance in Q3; 2018 guidance lowered.
BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.
Wright Medical (WMGI) Reports Q3 Loss, Raises '18 Guidance
by Zacks Equity Research
Growth in the upper and the lower extremity segments drives Wright Medical's (WMGI) Q3 results
Inogen (INGN) Q3 Earnings Beat, 2018 Revenue Guidance Up
by Zacks Equity Research
Inogen (INGN) gains from solid direct-to-consumer revenues in Q3; 2018 view up.
Genomic Health (GHDX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.
Intuitive Surgical (ISRG) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $540.02 in the latest trading session, marking a -1.04% move from the prior day.
DaVita's (DVA) Q3 Earnings Lag Estimates, Kidney Care Down
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in Q3; 2018 guidance narrowed.